血糖差预测大型多中心队列中COVID-19住院患者的死亡率
研究纳入美国东部5所大学医院2020年3月至2021年2月收治的1786例糖尿病或高血糖COVID-19住院患者,分析入院变量(含血糖差)与ICU入住、机械通气和死亡的关系。结果发现血糖差是比入院血糖或HbA1c更强的死亡预测因子(每mmol/L OR=1.040,95%CI:1.019,1.061,P<0.001)。
要点
- 血糖差(入院血糖减基于HbA1c估算的平均血糖)是比入院血糖或HbA1c更强的死亡预测因子(每mmol/L OR=1.040,95%CI:1.019,1.061,P<0.001)。
- 年龄(P<0.001)和入院血糖(P=0.014)与死亡风险增加相关,而HbA1c无此关联。
- 校正多变量模型中,血糖差、年龄、BMI和入院时糖尿病酮症酸中毒与死亡率增加相关,较高eGFR和使用任何糖尿病药物与死亡率降低相关(P<0.001)。
核心结论
- 入院血糖差所反映的相对高血糖是COVID-19死亡风险的重要标志物。
研究设计与样本
- 多中心队列研究,纳入美国东部5所大学医院2020年3月至2021年2月收治的1786例糖尿病或高血糖(24小时内两次血糖>10 mmol/L)COVID-19住院患者。
主要发现
- 队列中男性占51.3%,白人占53.3%,黑人占18.8%,西班牙裔占29.0%,年龄65.6±14.4岁,BMI 31.5±7.9 kg/m2,血糖12.0±7.5 mmol/L(216±135 mg/dL),HbA1c 8.07%±2.25%。
- 住院期间38.9%入住ICU,22.9%接受机械通气,10.6%死亡。
- 年龄(P<0.001)和入院血糖(P=0.014)与死亡风险增加相关,而HbA1c无此关联。
- 血糖差(入院血糖减基于HbA1c估算的平均血糖)是比入院血糖或HbA1c更强的死亡预测因子(每mmol/L OR=1.040,95%CI:1.019,1.061,P<0.001)。
- 校正多变量模型中,血糖差、年龄、BMI和入院时糖尿病酮症酸中毒与死亡率增加相关,较高eGFR和使用任何糖尿病药物与死亡率降低相关(P<0.001)。
关键数值与推荐
- 血糖差定义为入院血糖减去基于HbA1c估算的平均血糖。
- 血糖差每升高1 mmol/L,死亡OR=1.040(95%CI:1.019,1.061),P<0.001。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetes or hyperglycemia at admission are established risk factors for adverse outcomes during hospitalization for COVID-19, but the impact of prior glycemic control is not clear. OBJECTIVE: We aimed to examine the associations between admission variables, including glycemic gap, and adverse clinical outcomes in patients hospitalized with COVID-19 infection. METHODS: We examined the relationship between clinical predictors, including acute and chronic glycemia, and clinical outcomes, including intensive care unit (ICU) admission, mechanical ventilation (MV), and mortality among 1786 individuals with diabetes or hyperglycemia (glucose > 10 mmol/L twice in 24 hours) who were admitted from March 2020 through February 2021 with COVID-19 infection at 5 university hospitals in the eastern United States. RESULTS: The cohort was 51.3% male, 53.3% White, 18.8% Black, 29.0% Hispanic, with age = 65.6 ± 14.4 years, BMI = 31.5 ± 7.9 kg/m2, glucose = 12.0 ± 7.5 mmol/L [216 ± 135 mg/dL], and HbA1c = 8.07% ± 2.25%. During hospitalization, 38.9% were admitted to the ICU, 22.9% received MV, and 10.6% died. Age (P < 0.001) and admission glucose (P = 0.014) but not HbA1c were associated with increased risk of mortality. Glycemic gap, defined as admission glucose minus estimated average glucose based on HbA1c, was a stronger predictor of mortality than either admission glucose or HbA1c alone (OR = 1.040 [95% CI: 1.019, 1.061] per mmol/L, P < 0.001). In an adjusted multivariable model, glycemic gap, age, BMI, and diabetic ketoacidosis on admission were associated with increased mortality, while higher estimated glomerular filtration rate (eGFR) and use of any diabetes medication were associated with lower mortality (P < 0.001). CONCLUSION: Relative hyperglycemia, as measured by the admission glycemic gap, is an important marker of mortality risk in COVID-19.
引用
- McDonnell ME, Garg R, Gopalakrishnan G, et al. Glycemic Gap Predicts Mortality in a Large Multicenter Cohort Hospitalized With COVID-19. J Clin Endocrinol Metab. 2023. PMID: 36217580. doi:10.1210/clinem/dgac587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。